
NexoBrid®

Disruptive Bioactive Therapy for Burn Care



Eschar Removal


Critical First Step in Burn Care



Prevents infection and sepsis | Stops deterioration and scarring | Tissue visible for medical evaluation

Traumatic SOC[1]

Surgical, Non-Selective



Loss of healthy tissue and blood | Challenging in delicate areas | Requires surgical team, operating room

NexoBrid: Rapid, Effective, and Selective







- Sterile mixture of proteolytic enzymes
- Globally approved for eschar removal in adult and pediatric burn patients in 40+ countries
- 18,000+ patients treated to date
- Topical application at patient's bedside
- Minimizes need for surgery and significantly reduces blood loss
- Improves patient outcomes (scar quality and function) Removes eschar within 4 hours
- Enables visual medical assessment
- Extensive government funding: $138M received from BARDA and DoW
- Commercially available in U.S., EU, JP

[1] standard of care